Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Moe, Sharon M.; Chertow, Glenn M.; Parfrey, Patrick S.; Kubo, Yumi; Block, Geoffrey A.; Correa-Rotter, Ricardo; Drüeke, Tilman B.; Herzog, Charles A.; London, Gerard M.; Mahaffey, Kenneth W.; Wheeler, David C.; Stolina, Maria; Dehmel, Bastian; Goodman, William G.; Floege, Jürgen; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*. Circulation. 2015; 27-39: p.27-39. doi:10.1161/CIRCULATIONAHA.114.013876
    Article